Bright Minds Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023
— First-in-human Phase 1 trial for lead program, BMB-101, a highly selective 5-HT2C agonist, is underway inAustralia — — Company has transitioned from a discovery to a development organization – — Company to attend BIO-Europe Spring Conference in Basel, Switzerland, March 20-22, 2023 — – Vancouver, British Columbia, February 27, 2023 – Bright Minds…
